Annexin Pharmaceuticals AB (publ) (STO:ANNX)

Sweden flag Sweden · Delayed Price · Currency is SEK
14.50
+0.20 (1.40%)
At close: Mar 6, 2026
-54.69%
Market Cap 102.36M
Revenue (ttm) n/a
Net Income (ttm) -36.89M
Shares Out 7.06M
EPS (ttm) -5.58
PE Ratio n/a
Forward PE 5.22
Dividend n/a
Ex-Dividend Date n/a
Volume 4,896
Average Volume 6,677
Open 14.50
Previous Close 14.30
Day's Range 14.20 - 14.60
52-Week Range 13.40 - 41.20
Beta 0.12
RSI 42.25
Earnings Date May 13, 2026

About STO:ANNX

Annexin Pharmaceuticals AB (publ), a clinical stage biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases. It develops ANXV, a human recombinant protein and Annexin A5, natural protein that protects and repairs cells, as well as counteract unwanted inflammatory and immune cell reactions. Annexin Pharmaceuticals AB (publ) was incorporated in 2014 and is based in Stockholm, Sweden. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 4
Stock Exchange Nasdaq Stockholm
Ticker Symbol ANNX
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.